SCHEMBL23997307

SCHEMBL23997307

O=C(c1cccc(Cn2c(=O)[nH]c3ccccc32)c1)N1CCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.52
DRD2 P14416 1/20 0.52
ADRA1D P25100 1/20 0.52
ADRA1A P35348 1/20 0.52
ADRA1B P35368 1/20 0.52
LMNA P02545 3/20 0.51
HTT P42858 1/20 0.51
PARP1 P09874 1/20 0.49
FAAH O00519 1/20 0.49
MGLL Q99685 1/20 0.49
HSD11B1 P28845 3/20 0.48
ALDH1A1 P00352 1/20 0.48
CHRM1 P11229 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345086 1.00 HTR1A (0.52) HTR1ADRD2ADRA1DADRA1AADRA1B
SCHEMBL30345067 0.83 LMNA (0.58) LMNAHTTALDH1A1SMN1; SMN2MEN1
SCHEMBL23997344 0.83 LMNA (0.58) LMNAHTTALDH1A1SMN1; SMN2MEN1
SCHEMBL30427399 0.80 PARP1 (0.57) PARP1
SCHEMBL12822250 0.80 PARP1 (0.57) PARP1
SCHEMBL23997297 0.79 LMNA (0.53) LMNAHTTSMN1; SMN2MEN1KMT2A
SCHEMBL23997296 0.79 LMNA (0.53) DRD2LMNAHTTSMN1; SMN2MEN1
SCHEMBL30345095 0.79 LMNA (0.53) DRD2LMNAHTTSMN1; SMN2MEN1
SCHEMBL30456686 0.79 LMNA (0.53) LMNAHTTSMN1; SMN2MEN1KMT2A
SCHEMBL25720691 0.79 LMNA (0.53) LMNAHTTFAAHMGLLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 CN disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 HTR1A 4399/4885DRD2 4869/4885ADRA1D 2454/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 HTR1A 4399/4885DRD2 4869/4885ADRA1D 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.